Short answer
Annexon, Inc. (ANNX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter 2026 financial results announced for period ended September 30, 2026.
Annexon, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter 2026 financial results announced for period ended September 30, 2026
- Business updates and anticipated milestones included in Exhibit 99.1
- Investor focus: clinical-development progress and upcoming milestones alongside financial results
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue-free biotech reported net loss $51.2M, or $0.25 per share, versus $54.9M, or $0.37, prior year
- Cash, equivalents and short-term investments $213.4M at September 30, supporting anticipated operations into 2028
- Oxford credit facility up to $200M, including $50M drawn and $100M contingent on registrational milestones
- Tanruprubart BLA submission expected Q4 2026, while EU MAA review continues for GBS
- Vonaprument ARCHER II Month 15 endpoint assessment expected Q4 2026, creating the nearest major clinical catalyst for GA program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Annexon, Inc. 8-K filings
Get the next ANNX 8-K as it lands
Follow ANNX for push alerts, or ask the research agent what this filing means.